Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJohn Seibyl, MD
Professor AdjunctAbout
Research
Publications
2025
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study
Marek K, Russell D, Concha-Marambio L, Choi S, Jennings D, Brumm M, Coffey C, Brown E, Seibyl J, Stern M, Soto C, Siderowf A. Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study. EBioMedicine 2025, 112: 105567. PMID: 39893720, PMCID: PMC11835612, DOI: 10.1016/j.ebiom.2025.105567.Peer-Reviewed Original ResearchConceptsDementia with Lewy bodiesCross-sectional studyCognitive symptomsParkinson Associated Risk Syndrome StudyPrevention StudyYear Follow-UpOlder individualsDopamine transporter imagingHigh riskSyndrome studiesParticipantsParkinson's diseaseHyposmic individualsFollow-upSynuclein pathologySymptomsHyposmicsDepartment of DefenseU.S. Department of DefenseIndividualsRiskLewy bodiesClinical parkinsonismMichael J. Fox FoundationDementia
2024
Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies
Dilcher R, Wall S, Groß M, Katzdobler S, Wagemann O, Palleis C, Weidinger E, Fietzek U, Bernhardt A, Kurz C, Ferschmann C, Scheifele M, Zaganjori M, Gnörich J, Bürger K, Janowitz D, Rauchmann B, Stöcklein S, Bartenstein P, Villemagne V, Seibyl J, Sabri O, Barthel H, Perneczky R, Schöberl F, Zwergal A, Höglinger G, Levin J, Franzmeier N, Brendel M. Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies. Alzheimer's & Dementia 2024, 20: 6896-6909. PMID: 39263969, PMCID: PMC11485081, DOI: 10.1002/alz.14185.Peer-Reviewed Original ResearchGlutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001)
Brasic J, Nandi A, Russell D, Jennings D, Barret O, Slifer K, Sedlak T, Seibyl J, Berry-Kravis E, Wong D, Budimirovic D. Glutamatergic Dysfunction in Autism Spectrum Disorder (P1-8.001). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204347.Peer-Reviewed Original ResearchBiological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal α-synuclein Disease Integrated Staging System (NSD-ISS) (P11-3.009)
Tanner C, Simuni T, Chahine L, Poston K, Brumm M, Chowdry S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil C, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Poewe W, Marek K. Biological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal α-synuclein Disease Integrated Staging System (NSD-ISS) (P11-3.009). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000204771.Peer-Reviewed Original ResearchImproved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620
Bischof G, Brendel M, Barthel H, Theis H, Barbe M, Bartenstein P, Claasen J, Danek A, Höglinger G, Levin J, Marek K, Neumaier B, Palleis C, Patt M, Rullmann M, Saur D, Schroeter M, Seibyl J, Song M, Stephens A, Sabri O, Drzezga A, van Eimeren T, Tauopathies F. Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620. Journal Of Nuclear Medicine 2024, 65: jnumed.123.265930. PMID: 38575191, PMCID: PMC11149601, DOI: 10.2967/jnumed.123.265930.Peer-Reviewed Original ResearchTau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies
Ferschmann C, Messerschmidt K, Gnörich J, Barthel H, Marek K, Palleis C, Katzdobler S, Stockbauer A, Fietzek U, Finze A, Biechele G, Rumpf J, Saur D, Schroeter M, Rullmann M, Beyer L, Eckenweber F, Wall S, Schildan A, Patt M, Stephens A, Classen J, Bartenstein P, Seibyl J, Franzmeier N, Levin J, Höglinger G, Sabri O, Brendel M, Scheifele M. Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies. European Journal Of Nuclear Medicine And Molecular Imaging 2024, 51: 1909-1922. PMID: 38366196, PMCID: PMC11139736, DOI: 10.1007/s00259-024-06637-6.Peer-Reviewed Original ResearchA biological definition of neuronal α-synuclein disease: towards an integrated staging system for research
Simuni T, Chahine L, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil C, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner C, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. The Lancet Neurology 2024, 23: 178-190. PMID: 38267190, DOI: 10.1016/s1474-4422(23)00405-2.Peer-Reviewed Original Research
2023
Biomarker interplay between CSF p‐tau and 18F‐PI‐2620 PET in Alzheimer’s disease and 4R‐tauopathy
Dilcher R, Wall S, Franzmeier N, Katzdobler S, Barthel H, Wagemann O, Palleis C, Weidinger E, Fietzek U, Kurz C, Ferschmann C, Scheifele M, Eckenweber F, Zaganjori M, Gnörich J, Danek A, Bürger K, Janowitz D, Rauchmann B, Stöcklein S, Perneczky R, Schoeberl F, Zwergal A, Höglinger G, Bartenstein P, Villemagne V, Seibyl J, Sabri O, Levin J, Brendel M. Biomarker interplay between CSF p‐tau and 18F‐PI‐2620 PET in Alzheimer’s disease and 4R‐tauopathy. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.075969.Peer-Reviewed Original ResearchDopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure
Booij J, Tellier S, Seibyl J, Vriend C. Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure. Movement Disorders 2023, 38: 2131-2135. PMID: 37670567, DOI: 10.1002/mds.29597.Peer-Reviewed Original ResearchNeurotheranostics: The Next Frontier for Health Span
Losee M, Seibyl J, Kuo P. Neurotheranostics: The Next Frontier for Health Span. Journal Of Nuclear Medicine Technology 2023, 51: jnmt.123.265502. PMID: 37586855, DOI: 10.2967/jnmt.123.265502.Peer-Reviewed Original Research